Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

KRAS, an oncogene that is mutated in around 20% of tumours, is a major cancer conundrum. For decades, researchers thought that it was too smooth to drug, until a team found a hidden toehold on one ...

Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and ...

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day. In this study, the researchers used RAS(ON) multi-selective inhibitors, the ...

In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib (RMC-6236) and the preclinical tool compound RMC-7977 (both discovered by Revolution ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...